Polyubiquitylation of AMF requires cooperation between the gp78 and TRIM25 ubiquitin ligases

Oncotarget

Volumn 5, Issue 8, 2014, Pages 2044-2051

  Wang, Ying ^a   Ha, Seung Wook ^a   Zhang, Tianpeng ^a   Kho, Dhong Hyo ^a   Raz, Avraham ^a   Xie, Youming ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AMF; Gp78; Protein ubiquitylation; Trim25; Ubiquitin ligase

Indexed keywords

GLUCOSE 6 PHOSPHATE ISOMERASE; TRIPARTITE MOTIF PROTEIN 25; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE GP78; UNCLASSIFIED DRUG; AMFR PROTEIN, HUMAN; AUTOCRINE MOTILITY FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TRIM25 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; GENE OVEREXPRESSION; IN VITRO STUDY; MOLECULAR MECHANICS; PROTEIN DOMAIN; PROTEIN EXPRESSION; STEADY STATE; UBIQUITINATION; HEK293 CELL LINE; HUMAN; IMMUNOBLOTTING; IMMUNOPRECIPITATION; METABOLISM;

GLUCOSE-6-PHOSPHATE ISOMERASE; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; RECEPTORS, AUTOCRINE MOTILITY FACTOR; TRANSCRIPTION FACTORS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84899534051     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1478     Document Type: Article

References (38)

1. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998; 76: 425-479.
2. Varshavsky A. The N-end rule pathway and regulation by proteolysis. Protein Sci. 2011; 20: 1298-1345.
3. Harper JW, Tan M K. Understanding cullin-ring E3 biology through proteomics-based substrate identification. Mol Cell Proteomics. 2012; 11: 1541-1550.
4. Finley D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem. 2009; 78: 477-513.
5. Pickart CM. Back to the future with ubiquitin. Cell. 2004; 116: 181-190.
6. Ravid T, Hochstrasser M. Diversity of degradation signals in the ubiquitin-proteasome system. Nat Rev Mol Cell Biol. 2008; 9: 679-690.
7. Komander D, Rape M. The ubiquitin code. Annu Rev Biochem. 2012; 81: 203-229.
8. Ciechanover A, Ben-Saadon R. N-terminal ubiquitination: more protein substrates join in. Trends Cell Biol. 2002; 14: 103-106.
9. Koegl M, Hoppe T, Schlenker S, Ulrich HD, Mayer TU, Jentsch S. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell. 1999; 96: 635-644.
10. Hoppe T. Multiubiquitylation by E4 enzymes: 'one size" does not fit all. Trends Biochem. Sci. 2005; 30: 183-187.
11. Hwang CS, Shemorry A, Auerbach D, Varshavsky A. The N-end rule pathway is mediated by a complex of the RINGtype Ubr1 and HECT-type Ufd4 ubiquitin ligases. Nat Cell Biol. 2010; 12: 1177-1185.
12. Morito D, Hirao K, Oda Y, Hosokawa N, Tokunaga F, Cyr DM, Tanaka K, Iwai K, Nagata K. Gp78 cooperates with RMA1 in endoplasmic reticulum-associated degradation of CFTRΔF508. Mol Biol Cell. 2008; 19: 1328-1336.
13. Shi D, Pop MS, Kulikov R, Love IM, Kung AL, Grossman SR. CBP and p300 are cytoplasmic E4 polyubiquitin ligasesfor p53. Proc Natl Acad Sci USA. 2009; 106: 16275-16280.
14. Wu H, Leng RP. UBE4B, a ubiquitin chain assembly factor is required for MDM2-mediated p53 polyubiquitination and degradation. Cell Cycle. 2011; 10: 1912-1915.
15. Fang S, Ferrone M, Yang C, Jensen JP, Tiwari S, Weissman AM. The tumor autocrine motility factor receptor, gp78, is a ubiquitin protein ligase implicated in degradation from the endoplasmic reticulum. Proc Natl Acad Sci USA. 2001; 98: 14422-14427.
16. Chen B, Mariano J, Tsai YC, Chan AH, Cohen M, Weissman AM. The activity of a human endoplasmic reticulum-associated degradation E3, gp78, requires its Cue domain, RING finger, and an E2-binding site. Proc Natl Acad Sci USA. 2006; 103: 341-346.
17. Vembar SS, Brodsky JL. One step at a time: endoplasmic reticulum-associated degradation.Nat Rev Mol Cell Biol. 2008; 9: 944-957.
18. Christianson JC, Olzmann JA, Shaler TA, Sowa ME, Bennett EJ, Richter CM, Tyler RE, Greenblatt EJ, Harper JW, Kopito RR. Defining human ERAD networks through an integrative mapping strategy. Nat Cell Biol. 2012; 14: 93-105.
19. Buchberger A, Bukau B, Sommer T. Protein quality control in the cytosol and the endoplasmic reticulum: brothers in arms. Mol Cell. 2010; 40: 238-252.
20. Lee JN, Song B, DeBose-Boyd RA, Ye J. Sterol-regulated degradation of Insig-1 mediated by the membrane-bound ubiquitin ligase gp78. J Biol Chem. 2006; 281: 39308- 39315.
21. Liang JS, Kim T, Fang S, Yamaguchi J, Weissman AM. Overexpression of the tumor autocrine motility factor receptor Gp78, a ubiquitin protein ligase, results in increased ubiquitinylation and decreased secretion of apolipoprotein B100 in HepG2 cells. J Biol Chem. 2003; 278: 23984-23988.
22. Song BL, Sever N, DeBose-Boyd RA. Gp78, a membraneanchored ubiquitin ligase, associates with Insig-1 and couples sterol-regulated ubiquitylation to degradation of HMG CoA reductase. Mol Cell. 2005; 19: 829-840.
23. Ying Z, Wang H, Fan H, Zhu X, Zhou J, Fei E, Wang G. Gp78, an ER associated E3, promotes SOD1 and ataxin-3 degradation. Hum Mol Genet. 2009; 18: 4268-4281.
24. Ying Z , Wang H, Fan H, Wang G. The endoplasmic reticulum (ER)-associated degradation system regulates aggregation and degradation of mutant neuroserpin. J Biol Chem. 2011; 286: 20835-20844.
25. Pabarcus MK, Hoe N, Sadeghi S, Patterson C, Wiertz E, Correia MA. CYP3A4 ubiquitylation by gp78 (the tumor autocrine motility factor receptor, AMFR) and CHIP E3 ligases. Arch Biochem Biophys. 2009; 483: 66-74.
26. Shen Y, Ballar P, Fang S. Ubiquitin ligase gp78 increases solubility and facilitates degradation of the Z variant of alpha-1-antitrypsin. Biochem Biophys Res Commun. 2006; 349: 1285-1293.
27. Tsai YC, Mendoza A, Mariano JM, Zhou M, Kostova Z, Chen B, Veenstra T, Hewitt SM, Helman LJ, Khanna C, Weissman AM. The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation. Nat Med. 2007; 13: 1504-1509.
28. Nabi IR, Watanabe H, Raz A. Identification of B16-F1 melanoma autocrine motility-like factor receptor. Cancer Res. 1990; 50: 409-414.
29. Silletti S, Watanabe H, Hogan V, Nabi IR, Raz A. Purification of B16-F1 melanoma autocrine motility factor and its receptor. Cancer Res. 1991; 51: 3507-3511.
30. Funasaka T, Raz A. The role of autocrine motility factor in tumor and tumor microenvironment. Cancer Metastasis Rev. 2007; 26: 725-735.
31. Harrison RA. The detection of hexokinase, glucosephosphate isomerase and phosphoglucomutase activities in polyacrylamide gels after electrophoresis: a novel method using immobilized glucose 6-phosphate dehydrogenase. Anal Biochem. 1974; 61: 500-507.
32. Treier M, Staszewski LM, Bohmann D. Ubiquitindependent c-Jun degradation in vivo is mediated by the delta domain. Cell. 1994; 78: 787-798.
33. McNab FW, Rajsbaum R, Stoye JP, O'Garra A. Tripartitemotif proteins and innate immune regulation. Curr Opin Immunol. 2011; 23: 46-56.
34. Orimo A, Inoue S, Ikeda K, Noji S, Muramatsu M. Molecular cloning, structure, and expression of mouse estrogen-responsive finger protein Efp: Colocalization with estrogen receptor mRNA in target organs. J Biol Chem. 1995; 270: 24406-24413.
35. Gack MU, Shin YC, Joo C-H, Urano T, Liang C, Sun L, Takeuchi O, Akira S, Chen Z, Inoue S, Jung JU. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-Imediated antiviral activity. Nature. 2007; 446: 916-920.
36. Zou W, Zhang D-E. The interferon-inducible ubiquitinprotein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. J Biol Chem. 2006; 281: 3989-3994.
37. Nakasato N, Ikeda K, Urano T, Horie-Inoue K, Takeda S, Inoue S. A ubiquitin E3 ligase Efp is up-regulated by interferons and conjugated with ISG15. Biochem Biophys Res Commun. 2006; 351: 540-546.
38. Ju D, Wang X, Xu H, Xie Y. The armadillo repeats of the Ufd4 ubiquitin ligase recognize ubiquitin-fusion proteins. FEBS Lett. 2007; 581: 265-270.